Monday, January 11

6:00 p.m.-7:30 p.m. Opening Session

6:00 Welcome and Opening Remarks
Margaret Foti, American Association for Cancer Research
Philadelphia, PA
David P. Carbone, Vanderbilt-Ingram Cancer Center,
Nashville, TN
Roy S. Herbst, UT M. D. Anderson Cancer Center,
Houston, TX

6:30 Keynote Address
Studying Tumor Evolution in Mouse Models of Lung Cancer
Tyler Jacks, Massachusetts Institute of Technology,
Cambridge, MA

7:30 p.m.-8:30 p.m. Welcome Reception
Bay Terrace

Tuesday, January 12

7:00 a.m.-8:00 a.m. Continental Breakfast
Bay Terrace

8:00 a.m.-10:00 a.m. Plenary Session 1
Commodore ABCD

Tyrosine Kinase Signaling and Targeted Therapy
Co-Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, and William Pao, Vanderbilt University, Nashville, TN

8:00 Introduction
Matthew L. Meyerson

8:15 Discovery and clinical application of a novel oncogene, EML4-ALK, in lung cancer
Hiroyuki Mano, Jichi Medical University, Tochigi, Japan
Overcoming acquired resistance to EGFR inhibitors
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA

Targeting the insulin and insulin-like growth factor receptors: Efficacy and biology
Michael Pollak, McGill University, Montreal, Quebec

*Activation of c-Met by EGFR modulates invasive phenotypes in NSCLC
Austin M. Dulak, University of Pittsburgh, Pittsburgh, PA

10:00 a.m.-10:30 a.m. Break

10:30 a.m.-12:30 p.m. Plenary Session 2
Commodore ABCD

Early Detection for Premalignant Lesions and Field Cancerization
Co-Chairpersons: Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA, and Elisabeth M. P. Brambilla, Hôpital A. Michallon, Grenoble, France

10:30 NLST update and biospecimen opportunity
Denise R. Aberle

11:00 Airway gene expression as a biomarker for lung cancer
Avrum E. Spira, Boston University Medical Center, Boston, MA

11:30 Histone modification as an early mark of epigenetic change
Elisabeth M.P. Brambilla, Hôpital A. Michallon, Grenoble, France

12:00 *Sniffing NSCLC and SCLC using nanoparticle based artificial olfactory system NanoNose
Nir Peled, University of Colorado Cancer Center, Aurora, CO

12:15 *Blood-based biomarker profiles for detecting lung cancer
Gina Lee, David Geffen School of Medicine at UCLA, Los Angeles, CA

12:30 p.m.-2:30 p.m. Poster Session A and Lunch

2:30 p.m.-4:30 p.m. Concurrent Session 1
Constellation A

Detection and Prevention: From Mouse to Man
Co-Chairpersons: Steven M. Dubinett, UCLA David Geffen School of Medicine, Los Angeles, CA, and Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX
2:30  Personalized, targeted chemoprevention for lung cancer: Is it possible?  
Steven M. Dubinett

3:00  Moving prognostic epigenetic markers for lung cancer into the clinic  
Malcolm V. Brock, Johns Hopkins University, Baltimore, MD

3:30  Preclinical lung cancer chemoprevention models  
Robert L. Keith, University of Colorado Health Sciences Center, Denver, CO

4:00  Novel targets in metastasis prevention  
Jonathan M. Kurie

2:30 p.m.-4:30 p.m.  Concurrent Session 2  
Constellation B  
Other Thoracic Cancers (Mesothelioma, Thymic, Neuroendocrine)  
Co-Chairpersons: Pierre P. Massion, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY

2:30  Copy number alterations in the pathogenesis of small cell lung cancer  
Pierre P. Massion

3:00  Personalizing novel mesothelioma treatments for conventional and novel therapies  
Steven M. Albelda, University of Pennsylvania, Philadelphia, PA

3:30  Current insights into thymoma and thymic carcinoma  
Valerie W. Rusch

4:00  *Mouse models to study roles of TSG and signaling pathway in SCLC development  
Kwon-Sik Park, Stanford University, Stanford, CA.

4:15  *Matching phenotype-genotype interactions identifies mTOR as a druggable molecule in malignant pleural mesothelioma targeted therapeutic approach  
Giulia M. Stella, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
2:30 p.m.-4:30 p.m. Concurrent Session 3

**JAK/STAT Pathways as Therapeutic Targets**

Co-Chairpersons: Eric B. Haura, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, and Tetsuya Mitsudomi, Aichi Cancer Center Research Institute, Nagoya, Japan

2:30 Targeting JAK/STAT signaling for cancer therapy

**Richard Jove**, City of Hope, Duarte, CA

3:00 Targeting EGFR, Src, and Stat3 pathway for cancer therapy

**James Turkson**, University of Central Florida, Orlando, FL

3:30 Targeting STATs for the molecular therapy of lung cancer: Translation from the lab to the clinic

**David A. Frank**, Dana-Farber Cancer Institute, Boston, MA

4:00 JAK activation as a mechanism for resistance to c-Src inhibition in NSCLC

**Faye M. Johnson**, UT M. D. Anderson Cancer Center, Houston, TX

4:30 p.m.-6:00 p.m. Advocacy, Regulatory, and Funding Issues

Co-Chairpersons: Kim Norris, Lung Cancer Foundation of America, Palos Verdes Estates, CA, and Debra A. Violette, Dana-Farber Lung SPORE, Lung Cancer Alliance, Augusta, ME

4:30 Title TBD

**Lori Monroe**, Lung Cancer Foundation of America, Bowling Green, KY

5:00 Panel Discussion

**Wednesday, January 13**

7:00 a.m.-8:00 a.m. Continental Breakfast

Bay Terrace

8:00 a.m.-10:00 a.m. Plenary Session 3

**Cancer Stem Cells**

Co-Chairpersons: Stephen B. Baylin, Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, and John D. Minna, UT Southwestern Medical Center, Dallas, TX
8:00  *Lung cancer stem cells: Identification and translation to the clinic*
John D. Minna

8:30  *Epigenetic therapy, cancer self-renewing cells, and lung cancer*
Stephen B. Baylin

9:00  *Lung cancer stem cells and the cytokine network*
Vera Levina, University of Pittsburgh Cancer Institute, Pittsburgh, PA

9:30  *Lung cancer cells asymmetrically divide their template DNA strands during cell division*
Brid M. Ryan, National Cancer Institute, Bethesda, MD

9:45  *Targeting Rac1 GTPase benefits both human lung adenocarcinoma stem cell and non-stem cell therapies*
Shailaja Akunuru, Children’s Hospital Research Foundation, University of Cincinnati, Cincinnati, OH

10:00 a.m.-10:30 a.m.  Break  Commodore Foyer

10:30 a.m.-12:30 p.m.  Plenary Session 4  Commodore ABCD

**Genome-wide Approaches to Risk**
Co-Chairpersons: Bruce A. J. Ponder, CRUK, Cambridge Research Institute, Cambridge, UK, and Margaret R. Spitz, UT M. D. Anderson Cancer Center, Houston, TX

10:30  *Genome-wide approaches to risk: Lessons from breast and prostate*
Bruce A. J. Ponder

11:00  *Convergence of genetic findings for nicotine dependence and lung cancer*
Laura J. Bierut, Washington University School of Medicine, St. Louis, MO

11:30  *COPDGene: Risk factors for COPD and lung cancer*
James D. Crapo, University of Colorado Health Sciences Center, Denver, CO

12:00  *Identifying causal factors for lung cancer by genome wide studies*
Christopher I. Amos, UT M. D. Anderson Cancer Center, Houston, TX

12:30 p.m.-2:30 p.m.  Lunch (on own)
2:30 p.m.-4:30 p.m. Concurrent Session 4 Constellation A
Lung Cancer Profiling with microRNAs
Co-Chairpersons: Glen J. Weiss, Translational Genomics Research Institute, Phoenix, AZ, and Ignacio I. Wistuba, UT M. D. Anderson Cancer Center, Houston, TX

2:30 Application of miRNAs in the treatment of lung cancer
Glen J. Weiss

3:00 MicroRNA alterations in the pathogenesis of lung cancers
Takashi Takahashi, Nagoya University Graduate School of Medicine, Nagoya, Japan

3:30 MicroRNA binding site SNPs and lung cancer risk
Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT

4:00 *The role of microRNA 125a-3P in the pathogenesis of lung cancer
Saswati Hazra, David Geffen School of Medicine at UCLA, Los Angeles, CA

4:15 *MicroRNA affinity assay
Simon Spivack, Albert Einstein College of Medicine, Bronx, NY

2:30 p.m.-4:30 p.m. Concurrent Session 5 Constellation B
Mouse Models of Lung Cancer
Chairperson: Kwok-kin Wong, Dana-Farber Cancer Institute, Boston, MA

2:30 The use of genetically engineered mouse lung cancer models for preclinical testing of novel therapeutics
Kwok-kin Wong

3:00 The multiple roles of Kras in mouse epithelial cancer development
Minh D. To, UCSF Comprehensive Cancer Center, San Francisco, CA

3:30 Preclinical evaluation of genetically engineered mouse models of NSCLC and SCLC
Leisa Johnson, Genentech, Inc., South San Francisco, CA

4:00 *BRAF deletion and pharmacologic inhibition enhance KRAS-driven tumorigenesis
Christopher L. Murriel, Genentech, Inc., South San Francisco, CA

4:15 *Novel lung cancer model mediated by lentiviral gene delivery
Yifeng Xia, Salk Institute for Biological Studies, La Jolla, CA
2:30 p.m.-4:30 p.m. Concurrent Session 6

Other Biomarkers
Co-Chairpersons: David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Fred R. Hirsch, University of Colorado Cancer Center, Aurora, CO

2:30  Proteomics-based biomarker development in NSCLC
David P. Carbone

3:00  Gene copy number for EGFR and IGF-1R: Clinical implications
Fred R. Hirsch

3:30  Prognostic and predictive biomarkers for adjuvant chemotherapy
Ming Sound Tsao, Princess Margaret Hospital, Toronto, Canada

4:00  *High-throughput protein biomarker discovery and translation into clinical diagnostics for oncology using the SomaLogic SOMAmer-based assay
Rachel Ostroff, SomaLogic, Inc., Boulder, CO

4:15  *Gene expression changes in the bronchial airway epithelium of smokers with lung cancer may reflect common pathways of tobacco-related carcinogenesis
Adam C. Gower, Boston University, Boston, MA

4:30 p.m.-6:30 p.m. Poster Session B and Reception

Thursday, January 14

7:00 a.m.-8:00 a.m. Continental Breakfast
Bay Terrace

8:00 a.m.-10:00 a.m. Plenary Session 5

Angiogenesis and the Tumor Microenvironment
Co-Chairpersons: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX, and Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX

8:00  Antiangiogenic agents in the clinic: Are we there yet?
Joan H. Schiller

8:30  Molecular signature for bevacizumab in E4599
Heinz-Josef Lenz, USC/Norris Comprehensive Cancer Center, Los Angeles, CA
9:00  
Contrasting effects of different antiangiogenic drugs (TKIs and antibodies) on early- vs. late-stage metastatic disease  
Robert S. Kerbel, Sunnybrook Health Sciences Centre, Toronto, Canada

9:30  
*Phase II studies of ASA404 (vadimezan, DMXAA) plus carboplatin and paclitaxel in advanced squamous and nonsquamous non-small cell lung cancer: Blood and lymphatic adverse events  
M. J. McKeage, The University of Auckland, Auckland, New Zealand

9:45  
*Identification of tumor cell-derived factors associated with resistance to anti-VEGF therapy in non-small cell lung cancer  
Laura A. Sullivan, University of Texas Southwestern Medical Center, Dallas, TX

10:00 a.m.-10:30 a.m.  Break  
Commodore Foyer

10:30 a.m.-12:30 p.m.  Plenary Session 6  
Commodore ABCD  
Drug Design and New Targets  
Co-Chairpersons: Nagahiro Saijo, Kinki University School of Medicine, Osaka-Sayama, Japan, and David R. Gandara, UC Davis Cancer Center, Sacramento, CA

10:30  
Personalized therapeutic approaches for advanced NSCLC: The MDACC BATTLE program  
Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX

11:00  
Personalizing chemotherapy for advanced NSCLC  
David R. Gandara

11:30  
New targets for chemoprevention and therapy for lung cancer  
Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, TX

12:00  
New target discovery: A drug company perspective  
Mace L. Rothenberg, Pfizer, Inc., San Diego, CA

*Indicates proffered presentation from selected abstracts